Research ExplorerPublicationsRelation of Lipoprotein(a) Levels to Incident Type 2 Diabete...

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Standard

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. / Schwartz, Gregory G; Szarek, Michael; Bittner, Vera A; Bhatt, Deepak L; Diaz, Rafael; Goodman, Shaun G; Jukema, J Wouter; Loy, Megan; Manvelian, Garen; Pordy, Robert; White, Harvey D; Steg, Philippe Gabriel; ODYSSEY Outcomes Committees and Investigators.

In: DIABETES CARE, Vol. 44, No. 5, 05.2021, p. 1219-1227.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schwartz, GG, Szarek, M, Bittner, VA, Bhatt, DL, Diaz, R, Goodman, SG, Jukema, JW, Loy, M, Manvelian, G, Pordy, R, White, HD, Steg, PG & ODYSSEY Outcomes Committees and Investigators 2021, 'Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment', DIABETES CARE, vol. 44, no. 5, pp. 1219-1227. https://doi.org/10.2337/dc20-2842

APA

Schwartz, G. G., Szarek, M., Bittner, V. A., Bhatt, D. L., Diaz, R., Goodman, S. G., Jukema, J. W., Loy, M., Manvelian, G., Pordy, R., White, H. D., Steg, P. G., & ODYSSEY Outcomes Committees and Investigators (2021). Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. DIABETES CARE, 44(5), 1219-1227. https://doi.org/10.2337/dc20-2842

Vancouver

Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG et al. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. DIABETES CARE. 2021 May;44(5):1219-1227. https://doi.org/10.2337/dc20-2842

Bibtex

@article{de5be924aca04297a8abf39197024311,
title = "Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment",
abstract = "OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.RESEARCH DESIGN AND METHODS: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data.RESULTS: Among 13,480 patients without diabetes at baseline, 1,324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated with hazard ratio 1.04 (95% CI 1.02-1.06, P < 0.001) for incident type 2 diabetes. Alirocumab reduced lipoprotein(a) by a median 23.2% with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes (hazard ratio 0.95, 95% CI 0.85-1.05). At low baseline lipoprotein(a) levels, alirocumab tended to reduce incident type 2 diabetes, while at high baseline lipoprotein(a) alirocumab tended to increase incident type 2 diabetes compared with placebo (treatment-baseline lipoprotein(a) interaction P = 0.006). In the alirocumab group, a 10 mg/dL decrease in lipoprotein(a) from baseline was associated with hazard ratio 1.07 (95% CI 1.03-1.12; P = 0.0002) for incident type 2 diabetes.CONCLUSIONS: In patients with acute coronary syndrome, baseline lipoprotein(a) concentration associated inversely with incident type 2 diabetes. Alirocumab had neutral overall effect on incident type 2 diabetes. However, treatment-related reductions in lipoprotein(a), more pronounced from high baseline levels, were associated with increased risk of incident type 2 diabetes. Whether these findings pertain to other therapies that reduce lipoprotein(a) is undetermined.",
keywords = "Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Diabetes Mellitus, Type 2/drug therapy, Double-Blind Method, Humans, Lipoprotein(a), Proprotein Convertase 9, Treatment Outcome",
author = "Schwartz, {Gregory G} and Michael Szarek and Bittner, {Vera A} and Bhatt, {Deepak L} and Rafael Diaz and Goodman, {Shaun G} and Jukema, {J Wouter} and Megan Loy and Garen Manvelian and Robert Pordy and White, {Harvey D} and Steg, {Philippe Gabriel} and {ODYSSEY Outcomes Committees and Investigators}",
note = "{\textcopyright} 2021 by the American Diabetes Association.",
year = "2021",
month = may,
doi = "10.2337/dc20-2842",
language = "English",
volume = "44",
pages = "1219--1227",
journal = "DIABETES CARE",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

AU - Schwartz, Gregory G

AU - Szarek, Michael

AU - Bittner, Vera A

AU - Bhatt, Deepak L

AU - Diaz, Rafael

AU - Goodman, Shaun G

AU - Jukema, J Wouter

AU - Loy, Megan

AU - Manvelian, Garen

AU - Pordy, Robert

AU - White, Harvey D

AU - Steg, Philippe Gabriel

AU - ODYSSEY Outcomes Committees and Investigators

N1 - © 2021 by the American Diabetes Association.

PY - 2021/5

Y1 - 2021/5

N2 - OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.RESEARCH DESIGN AND METHODS: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data.RESULTS: Among 13,480 patients without diabetes at baseline, 1,324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated with hazard ratio 1.04 (95% CI 1.02-1.06, P < 0.001) for incident type 2 diabetes. Alirocumab reduced lipoprotein(a) by a median 23.2% with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes (hazard ratio 0.95, 95% CI 0.85-1.05). At low baseline lipoprotein(a) levels, alirocumab tended to reduce incident type 2 diabetes, while at high baseline lipoprotein(a) alirocumab tended to increase incident type 2 diabetes compared with placebo (treatment-baseline lipoprotein(a) interaction P = 0.006). In the alirocumab group, a 10 mg/dL decrease in lipoprotein(a) from baseline was associated with hazard ratio 1.07 (95% CI 1.03-1.12; P = 0.0002) for incident type 2 diabetes.CONCLUSIONS: In patients with acute coronary syndrome, baseline lipoprotein(a) concentration associated inversely with incident type 2 diabetes. Alirocumab had neutral overall effect on incident type 2 diabetes. However, treatment-related reductions in lipoprotein(a), more pronounced from high baseline levels, were associated with increased risk of incident type 2 diabetes. Whether these findings pertain to other therapies that reduce lipoprotein(a) is undetermined.

AB - OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.RESEARCH DESIGN AND METHODS: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data.RESULTS: Among 13,480 patients without diabetes at baseline, 1,324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated with hazard ratio 1.04 (95% CI 1.02-1.06, P < 0.001) for incident type 2 diabetes. Alirocumab reduced lipoprotein(a) by a median 23.2% with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes (hazard ratio 0.95, 95% CI 0.85-1.05). At low baseline lipoprotein(a) levels, alirocumab tended to reduce incident type 2 diabetes, while at high baseline lipoprotein(a) alirocumab tended to increase incident type 2 diabetes compared with placebo (treatment-baseline lipoprotein(a) interaction P = 0.006). In the alirocumab group, a 10 mg/dL decrease in lipoprotein(a) from baseline was associated with hazard ratio 1.07 (95% CI 1.03-1.12; P = 0.0002) for incident type 2 diabetes.CONCLUSIONS: In patients with acute coronary syndrome, baseline lipoprotein(a) concentration associated inversely with incident type 2 diabetes. Alirocumab had neutral overall effect on incident type 2 diabetes. However, treatment-related reductions in lipoprotein(a), more pronounced from high baseline levels, were associated with increased risk of incident type 2 diabetes. Whether these findings pertain to other therapies that reduce lipoprotein(a) is undetermined.

KW - Antibodies, Monoclonal, Humanized

KW - Anticholesteremic Agents

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Double-Blind Method

KW - Humans

KW - Lipoprotein(a)

KW - Proprotein Convertase 9

KW - Treatment Outcome

U2 - 10.2337/dc20-2842

DO - 10.2337/dc20-2842

M3 - SCORING: Journal article

C2 - 33722880

VL - 44

SP - 1219

EP - 1227

JO - DIABETES CARE

JF - DIABETES CARE

SN - 0149-5992

IS - 5

ER -